Tecnofarma Expands In Brazil, Boosts Output

Latin American pharmaceutical group Tecnofarma is to expand its Zodiac unit in Brazil, spending some BRL12mn (US$5.6mn) on acquiring new brands in the oncology segment. The company is adding new products aimed at the US$350mn cancer sector to its portfolio, following successful licensing deals with Chiron and Hexal, both units of Switzerland's Novartis, as well as with US giant Pfizer. Zodiac's parent firm also expects to launch its first proprietary cancer drug in the

To read the full article, please choose one of the following options: